(Updated - August 9, 2022 3:59 AM EDT)

Goldman Sachs analyst Madhu Kumar raised the price target on Apellis ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change

Stifel Reiterates Buy Rating on Apellis Pharmaceuticals (APLS), 'we think the entire package presents a relatively convincing picture'August 9, 2022 4:02 AM Cowen Reiterates Outperform Rating on Apellis Pharmaceuticals (APLS), 'We Remain Optimistic For Pegcetacoplan Approval'August 9, 2022 4:01 AM Roth Capital Reiterates Sell Rating on Apellis Pharmaceuticals (APLS), Street Low $40 PTAugust 9, 2022 3:58 AM UPDATE: Apellis Pharmaceuticals (APLS) PT Raised to Street High $113 at Raymond JamesAugust 9, 2022 3:57 AM UPDATE: Apellis Pharmaceuticals (APLS) PT Raised to $52 at Credit SuisseAugust 9, 2022 3:34 AM Apellis Pharmaceuticals, Inc. (APLS) Misses Q2 EPS by 5cAugust 8, 2022 4:18 PM Apellis Pharmaceuticals Reports Second Quarter 2022 Financial ResultsAugust 8, 2022 4:06 PM Apellis Pharmaceuticals Reports Second Quarter 2022 Financial ResultsAugust 8, 2022 4:05 PM Form 4 Apellis Pharmaceuticals, For: Aug 04 Filed by: DeLong Mark JeffreyAugust 8, 2022 4:03 PM Form 10-Q Apellis Pharmaceuticals, For: Jun 30August 8, 2022 4:03 PM